Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
NASDAQ:ENTX
Price:
1.26
USD
10.53%
Market Closed
Market Cap:
$57.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Entera Bio Ltd
NASDAQ:ENTX
|
IL |
|
M
|
Modi Rubber Ltd
NSE:MODIRUBBER
|
IN |
|
A
|
Aurubis AG
OTC:AIAGF
|
DE |
|
A
|
Aluko Co Ltd
KRX:001780
|
KR |
|
Seabridge Gold Inc
TSX:SEA
|
CA |
|
InterDigital Inc
NASDAQ:IDCC
|
US |
|
M
|
Myanmar Investments International Ltd
LSE:MIL
|
SG |
|
GreenX Metals Ltd
LSE:GRX
|
AU |
|
Merriman Holdings Inc
OTC:MERR
|
US |
|
FIC Global Inc
TWSE:3701
|
TW |
|
D
|
DTC Industries PCL
SET:DTCI
|
TH |
|
Direct Marketing MiX Inc
TSE:7354
|
JP |
|
A
|
Atlas Consolidated Mining and Development Corp
XPHS:AT
|
PH |
|
Vytrus Biotech SA
MAD:VYT
|
ES |
|
J
|
Jiangmen Kanhoo Industry Co Ltd
SZSE:300340
|
CN |
|
P
|
Piotech Inc
SSE:688072
|
CN |
|
S
|
Sbf AG
F:CY1K
|
DE |
|
Alimera Sciences Inc
NASDAQ:ALIM
|
US |
|
Hardide PLC
LSE:HDD
|
UK |
Multiples-Based Value
The Multiples-Based Value of one
ENTX
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.26 USD,
Entera Bio Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ENTX Multiples-Based Value
LOCKED
Multiples Across Competitors
ENTX Competitors Multiples
Entera Bio Ltd Competitors
Entera Bio Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Entera Bio Ltd
NASDAQ:ENTX
|
57.5m USD | 464 | -5.3 | -4.5 | -4.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
